Log In
BCIQ
Print this Print this
 

H4+IC31, H4IC (AERAS-404)

  Manage Alerts
Collapse Summary General Information
Company Aeras Global TB Vaccine Foundation
DescriptionVaccine that consists of a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4 combined with the IC31 adjuvant
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationTuberculosis
Indication DetailsPrevent Mycobacterium tuberculosis infection
Regulatory Designation
PartnerSanofi;
Statens Serum Institut;
Valneva SE

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today